After Aeterna Zentaris announced that a phase 3 trial failed to achieve its objective of validating a single oral dose of macimorelin for the evaluation of growth hormone deficiency in adults, Maxim analyst Jason Kolbert completely removed Macrilen from his model and cut his price target on the stock to $7 from $10. However, he keeps a Buy rating on Aeterna, noting Zoptrex is currently in the final stages of a fully enrolled pivotal Phase 3 study in EC, adding that if the data are positive as he thinks they will be that the company could file an NDA in the first half of 2017.